The immuno-oncology antibody developer added $7m from Helsinn and GreatPoint to a round already containing Baxalta, MD Anderson and Alexandria Real Estate Equities.
OncoResponse, a US-based company researching antibodies for immune-oncology treatments, added $7m yesterday to a corporate-backed series A round that now totals $19.5m.
Helsinn Investment Fund, the unit recently launched by cancer care provider Helsinn, and venture capital firm GreatPoint Ventures each provided $3.5m. Baxalta, the biopharmaceutical company since acquired by pharmaceutical firm Shire, had invested $3m in June 2016.
Arch Venture Partners, Canaan Partners and cancer treatment centre MD Anderson co-led the $9.5m first tranche of the…